Jade Biosciences, Inc. JBIO · SEC Filings

website

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation ...

Price15.6

Market Cap992.12 M

Float51.97 M

CountryUS

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

Financials

TYPE

HEADLINE

FILED AT

News

TYPE

HEADLINE

FILED AT

8-K

Jade Biosciences Announces Preclinical Data for JADE301 and Outlines Phase 1 Clinical Timeline

Sep 30, 2026

8-K

Jade Biosciences Reports Q2 2026 Financial Results and Pipeline Progress

Aug 10, 2026

8-K

Jade Biosciences Enters Exclusive Licensing Agreement with Paragon Therapeutics for Antibody Development

Jul 1, 2026

8-K

Jade Biosciences Appoints Dr. Mark Eisner to Board of Directors

Jun 26, 2026

8-K

Jade Biosciences, Inc. Announces Results of 2026 Annual Meeting and Governance Updates

Jun 11, 2026

8-K

Jade Biosciences Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Jun 4, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Jun 4, 2026

424B5

PENDING FIXED PRICE OFFERING | Bank: Jefferies

Jun 3, 2026

424B3

SHARE RESALE REGISTRATION | Shares: 39,542,339

May 15, 2026

424B3

SHARE RESALE REGISTRATION

May 7, 2026

424B3

SHARE RESALE REGISTRATION

May 7, 2026

424B3

SHARE RESALE REGISTRATION

Mar 6, 2026

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 7, 2026

S-3

SHARE RESALE REGISTRATION

May 7, 2026

S-3

[No Baby Shelf]* May 2026 SHELF and ATM

May 7, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 6, 2026

POS EX

Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]

Mar 6, 2026

POS EX

Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]

Mar 6, 2026

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Jun 5, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 17, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 26, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 26, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Other

TYPE

HEADLINE

FILED AT